Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer

Clinical and Translational Medicine - Tập 1 Số 1 - 2012
Belinda Seto1
1National Institutes of Health, National Institute of Biomedical Imaging and Bioengineering, 9000 Rockville Pike, Building 31, Room 1C14, 20892 Bethesda, MD, USA

Tóm tắt

AbstractRapamycin was discovered more than thirty years ago from a soil sample from the island of Rapa Nui. It was isolated from Streptomyces hygroscopicus and initial characterization focused on its antifungal activities. Subsequent characterization showed that it has immunosuppressive properties and has been used successfully to reduce organ rejection with kidney transplantation. Rapamycin has proven to be a versatile compound with several seemingly unrelated properties, including antifungal, immunosuppressive, and anticancer. The National Cancer Institute (NCI) Developmental Therapeutics Program demonstrated that rapamycin inhibited cell growth in tumor cell lines. These observations stimulated research to explore the underlying mechanism of anti‐tumor activities. Cell growth inhibition involves binding to the mammalian Target of Rapamycin (mTOR). The mTOR signaling pathway is critical to cell growth, proliferation, and survival and rapamycin inhibits these hallmark processes of cancer. Binding of growth factors activates mTOR signaling, which in turn leads to downstream phosphorylation of protein kinases, e.g., p70S6 kinase and lipid kinases in the phosphorylation of phosphoinositides. Understanding of mTOR signaling provided the biological basis for targeted chemotherapeutics development, including several rapamycin analogues for treating breast and other cancers.

Từ khóa


Tài liệu tham khảo

Breast Cancer:http://www.cancer.gov/cancertopics/types/breast.

10.1118/1.2903436

Centers for Disease Control and Prevention, 2007, Decline in breast cancer incidence – United States, 1999‐2003, Morb Mortal Wkly Rep, 56, 549

10.1002/j.1875-9114.2012.01084.x

10.7164/antibiotics.28.727

10.1146/annurev.immunol.14.1.483

Rapamune:http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000273/human_med_001010.jsp&mid=WC0b01ac058001d124.

10.1093/jnci/93.20.1517

10.1016/S0305-7372(81)80006-0

10.1016/S1471-4892(03)00071-7

10.1016/S1535-6108(03)00275-7

Heitman J, 1991, Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast, Science (New York, NY), 253, 905, 10.1126/science.1715094

10.1101/gad.845700

10.1101/gad.835000

10.1016/S0960-9822(02)01091-6

10.1128/MCB.19.6.4101

10.1073/pnas.092141899

10.1101/gad.1212704

10.1101/gr.084038.108

Janus A, 2005, The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy, Cell Mol Biol Lett, 10, 479

10.1016/j.drup.2008.03.001

10.1128/MMBR.69.1.79-100.2005

10.1593/neo.12542

10.1016/S0092-8674(02)01009-7

10.1016/S0092-8674(00)00117-3

10.1016/j.molcel.2003.08.016

10.1038/nrm3025

10.1038/sj.onc.1207542

10.1101/gad.995802

10.1016/j.cell.2006.01.016

10.1016/0092-8674(92)90643-Q

10.1073/pnas.011528498

10.1007/978-3-642-56688-2_5

10.1038/onc.2008.245

10.1186/bcr3039

Inc. WP, 2010, TORISEL Kit (etmsirolimus) injection, for intravenous infusion only package insert

Corporation. NP, 2011, AFINITOR (everolimus) tablets for oral administration package insert

10.1007/s10549-010-0986-9

10.1016/j.critrevonc.2007.06.010

10.1200/JCO.2011.39.0708

10.1200/JCO.2010.32.2321

10.1007/s10549-010-1260-x

10.1200/JCO.2009.27.8549

10.1016/j.jsbmb.2005.04.025

10.1158/1078-0432.CCR-04-0035

10.1038/nrc2713

10.3816/CBC.2006.n.047

10.1016/j.ejca.2007.10.003

FDA approves Afinitor for advanced breast cancer:http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312965.htm.

Developmental Therapeutics Program (DTP):http://dctd.cancer.gov/ProgramPages/dtp/default.htm.

10.1016/S0140-6736(11)60070-6

Molecular Libraries and Imaging:http://commonfund.nih.gov/molecularlibraries/index.aspx. doi:https://doi.org/10.1186/2001‐1326‐1‐29

Thông tin
Thông tin xuất bản

Clinical and Translational Medicine

Tập 1 Số 1

Thông tin tác giả